BioInformant

Your Global Leader in Stem Cell Market Research

  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • News
    • Interviews
  • Advertise
  • Shop
  • Company
    • Story
    • Testimonials
    • Submit PR
    • Job Posts
    • Privacy Policy
    • Guarantee
    • Contact
Home » Ncardia

Ncardia and Nanion Technologies Align Forces to Accelerate Drug Discovery & Development

October 1, 2018 By Cade Hildreth (CEO)

Ncardia, merger of Axiogenesis & Pluriomics

Major news broke in the iPSC sector last week when Ncardia (Cologne, Germany) and Nanion Technologies (Munich, Germany) signed a joint marketing and sales promotion agreement. Under the terms of partnership, customers of the companies will get access to high-performance instrument platforms from Nanion, coupled with Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. [Read more…]

4.8 / 5 ( 17 votes )

Filed Under: iPS Cells, News Tagged With: iPSC, Nanion, Ncardia

Ncardia to Host U.S. User Symposium (June 13-14, Boston)

May 24, 2018 By Cade Hildreth (CEO)

Ncardia, merger of Axiogenesis & Pluriomics

On June 13-14, 2018, in Boston, Massachusetts, Ncardia will host its Annual U.S. User Symposium. The event will showcase the use of Ncardia’s flagship hiPSC-derived cardiac models (Cor.4U® and Pluricyte®) and its hiPSC-derived neural cell products by key leaders in pharma and research.

Importantly, it will explore how experts in the pharmaceutical and biotechnology industry and leading academic institutions are using Ncardia’s first in class cells and assays in drug discovery, safety and toxicology screening, disease modelling and bioengineering. It will also present current approaches to establish and define standards for these cellular models.

Expected to be widely attended by representatives from the pharmaceutical sector, symposium attendees will view case studies of iPS cells in drug development decision-making and biomedical research and have the opportunity to exchange and share experiences with their peers.

[Read more…]

Filed Under: iPS Cells, News Tagged With: conference, Ncardia

ACEA Biosciences and Ncardia Partner to Provide Solutions for Cardiac Drug Discovery and Cardiac Safety Assessment

November 30, 2017 By Cade Hildreth (CEO)

Ncardia and ACEA Biosciences
November 30, 2017, San Diego and Cologne, Germany–ACEA Biosciences (ACEA), a pioneer and leader in label-free real-time cell analysis instrumentation, and Ncardia, a leading expert in human cardiovascular stem cell technology, disease modelling and cell-based assay products and services, announced today that they have established a global partnership to provide comprehensive solutions for cardiac drug discovery and cardiac safety assessment. This multifaceted partnership will include the joint development of applications, co-marketing, and commercial activities. Central to this partnership will be the coupling of ACEA’s innovative xCELLigence® Real-Time Cell Analysis (RTCA) Cardio and CardioECR instruments with Ncardia’s fully functional Pluricyte® and Cor.4U® human iPSC-derived cardiomyocytes, providing a complete assay system for pure and applied cardiomyocyte research.

[Read more…]

Filed Under: iPS Cells Tagged With: ACEA Biosciences, cardiac, Ncardia

Ncardia Signs License Agreement with Roche for Disease Modeling Patent Portfolio

October 12, 2017 By Cade Hildreth (CEO)

Ncardia and Roche License Agreement

Ncardia, merger of Axiogenesis & Pluriomics

Ncardia Signs License Agreement with First Pharmaceutical Partner for Disease Modeling Patent Portfolio

October 12, 2017, COLOGNE, Germany–Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate companies gain access to key disease modeling patents from Ncardia.

Ncardia was recently formed through the merger of Axiogenesis and Pluriomics. The two companies have pioneered the development of stem cell derived cells for drug discovery and safety and in particular have advanced disease and tissue modeling applications.

The Ncardia patent portfolio consists of several granted patents in Europe, the USA and Japan. The drug screening and disease modeling technology not only involves patient iPSC cells, induction of the disease phenotype can also be achieved through genetic manipulation, mRNA or siRNA transfection or through chemical or physical induction. [Read more…]

Filed Under: iPS Cells Tagged With: Ncardia, roche

NCardia, a Global Force in hiPSC Drug Discovery and Development Products and Solutions

September 18, 2017 By Cade Hildreth (CEO)

Ncardia, Axiogenesis and Pluriomics

Axiogenesis AG and Pluriomics B.V. are combining forces to form Ncardia, the new global authority in cardiac and neural applications of human induced pluripotent stem cells (iPSCs).

Ncardia, merger of Axiogenesis & PluriomicsFounded in 2001, Axiogenesis AG has Cologne (DE) and Philadelphia (USA) facilities, while Pluriomics B.V. has facilities in Gosselies (BE) and Leiden (NL). By entering into this merger, these European leaders will become the global leader in hiPSC drug discovery and development field, making Ncardia the partner of choice for scientists conducting cardiovascular and neural safety and efficacy projects.

By combining their global client base, the merger of Axiogenesis and Pluriomics will position Ncardia as a leader in standardized, validated iPSC assays for safety, phenotypic screening and disease modelling. For scientists conducting cardiovascular and neural safety and efficacy projects, Ncardia will provide tools to facilitate accelerated development of drugs, while replacing animal studies and putting a “human” aspect back into drug discovery.

NcardiaAccording to Felix Haniel, VP Business Development & Sales of Ncardia: “Our vision is to develop products and services that are a complete solution. We will produce human iPSC derived cardiovascular and neuronal cell types and realize validated electrophysiology, biochemistry and contraction based assays. By combining over two decades of experience, Ncardia will offer iPSC assays for safety pharmacology, toxicology testing, drug efficacy screening, phenotypic screening, and disease modelling.”

Founded in 2001 as a spin-off of the University of Cologne, Axiogenesis initially focused on generating mouse embryonic stem cell derived cells and assays. After Yamanaka’s groundbreaking iPSC technology became available, Axiogenesis was the first European company to license and adopt Yamanaka’s iPSC technology in 2010. Now Axiogenesis specializes in human induced pluripotent stem cell products, including in vitro models of healthy and diseased cell types and tissues. In 2014, Axiogenesis founded its American subsidiary in Philadelphia, PA. [Read more…]

4.6 / 5 ( 8 votes )

Filed Under: iPS Cells Tagged With: Axiogenesis, Ncardia, Pluriomics

  • 1
  • 2
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Aspire

Marathon Products

Cellevate

Perinatal Stem cell Society

Menu
  • Blog
  • News
  • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected $197
  • Global Database of Stem Cell Therapy Companies - Featuring 100+ Companies $39
  • Defining the Future of the Stem Cell Industry: Interviews with Stem Cell Executives $197 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Disclaimer

Copyright © 2019 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.